Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Lisata Therapeutics Inc. (LSTA) is a clinical-stage biopharmaceutical company pioneering novel peptide-based therapies for advanced solid tumors. This dedicated news hub provides investors and researchers with essential updates on the company's progress in enhancing cancer treatment through innovative drug delivery systems.
Access timely reports on clinical trial developments, strategic research partnerships, and regulatory milestones related to Lisata's lead candidate certepetide and its CendR Platform technology. Our curated collection includes press releases on trial initiations, scientific presentations, and corporate announcements that demonstrate the company's evolving role in oncology therapeutics.
Key updates cover advancements in pancreatic cancer research, glioblastoma treatment studies, and collaborative projects with academic institutions. The resource serves as a centralized reference for tracking how Lisata's tumor-penetrating peptide technology may improve existing cancer treatment paradigms through enhanced drug delivery mechanisms.
Bookmark this page for structured access to verified information about Lisata's clinical programs and corporate developments. Check regularly for new insights into the company's efforts to address unmet needs in solid tumor oncology through targeted therapeutic strategies.
Lisata Therapeutics (NASDAQ: LSTA) has entered into a research license agreement with Catalent to evaluate the combination of Lisata's certepetide with Catalent's SMARTag® antibody-drug conjugate (ADC) platform for treating advanced solid tumors.
Under the agreement, Catalent will fund all research and development while Lisata provides consulting support. Lisata will receive an upfront payment and potential future considerations based on preclinical evaluation results.
The collaboration aims to enhance ADC therapy by combining certepetide's tumor penetration capabilities with ADC's targeted delivery of cytotoxic drugs. This combination could potentially improve treatment efficacy while reducing systemic toxicity. Additionally, certepetide is expected to reduce the immunosuppressive nature of the tumor microenvironment (TME), potentially improving patient response to ADC therapy.
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on therapies for advanced solid tumors and other serious diseases, announced that its President and CEO, David J. Mazzo, Ph.D., will present at the Investival Showcase USA. The event is scheduled for March 10-11, 2025, in Miami, Florida.
Dr. Mazzo's presentation will occur on March 11th at 11:30 a.m. Eastern Time. For more information about the conference and registration details, please click here.
Lisata Therapeutics (NASDAQ: LSTA) and GATC Health have initiated a strategic collaboration leveraging GATC's AI-powered Multiomics Advanced Technology™ (MAT) platform to optimize and accelerate drug development. The partnership's first phase will analyze Lisata's investigational drug certepetide, focusing on optimizing its Phase 3 development for metastatic pancreatic ductal adenocarcinoma (mPDAC) and identifying new potential indications.
The collaboration will proceed in multiple steps: First, analyzing certepetide's potential applications; second, identifying potential drug combinations across various indications; and finally, establishing Lisata as GATC's operational partner for developing GATC's drug candidates. GATC's MAT AI platform simulates billions of biological interactions to predict safety, efficacy, and clinical trial outcomes.
This partnership aims to address traditional drug development challenges, including high failure rates (1 in 10,000 drugs reach market) and lengthy development timelines, by enabling more focused studies and optimized capital management through AI-driven analysis.
Lisata Therapeutics (NASDAQ: LSTA) has reported its full year 2024 financial results and provided updates on its development portfolio. The company's primary focus is on certepetide, a novel treatment for advanced solid tumors. Key highlights include promising preliminary Phase 2b (ASCEND) pancreatic cancer data from Cohort A, with Cohort B data expected in coming months.
Financial results show revenue of $1.0 million from a Kuva Labs licensing agreement, while operating expenses decreased 8.9% to $23.4 million. Net losses were $20.0 million for 2024, compared to $20.8 million in 2023. The company maintains a strong financial position with $31.2 million in cash and equivalents, providing runway into Q2 2026.
Multiple clinical trials are advancing, including ASCEND, BOLSTER, CENDIFOX, and iLSTA, evaluating certepetide across various cancer types. The company received $0.9 million in non-dilutive funding through New Jersey's Tax Certificate Transfer Program.
Lisata Therapeutics (LSTA), a clinical-stage pharmaceutical company focused on advanced solid tumor treatments, has scheduled its full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results and provide a business update.
Participants must pre-register for the conference call through a provided link. Registered attendees will receive dial-in details via email. To ensure smooth participation, attendees are encouraged to dial in 15 minutes before the scheduled start time. A live webcast will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months after the call.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its participation in the upcoming 2025 BIO CEO & Investor Conference.
The company's President and CEO, David J. Mazzo, PhD, will deliver a corporate overview presentation on Monday, February 10th at 2:00 p.m. Eastern Time. The conference is scheduled to take place from February 10-11, 2025, at the New York Marriott Marquis in New York City.
Lisata Therapeutics (NASDAQ: LSTA) and WARPNINE announced encouraging preliminary results from their Phase 1b/2a iLSTA trial evaluating certepetide in combination with standard-of-care (SoC) chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC).
The trial, conducted at St John of God Subiaco Hospital, involved 30 patients in three cohorts. Key preliminary results from 17 patients showed:
- 9 of 16 patients achieved partial response after 4 treatment cycles
- 1 patient exhibited complete response
- 14 of 17 patients showed decreased CA19-9 levels, with 6 patients showing >90% reduction
- All 5 analyzed patients showed significant immune cell infiltration (15% to 50%)
The data suggests certepetide's potential to enhance the effectiveness of various cancer treatments when combined with SoC chemotherapy and immunotherapy.
Lisata Therapeutics (NASDAQ: LSTA) announced preliminary Cohort A data from its Phase 2 ASCEND trial evaluating certepetide with standard chemotherapy in metastatic pancreatic ductal adenocarcinoma. The trial, conducted across 25 sites in Australia and New Zealand, showed encouraging results with a median overall survival of 12.68 months in the certepetide group versus 9.72 months in the placebo group.
The study reported 4 complete responses (6.2%) in the certepetide treatment group compared to none in the placebo group. While the 6-month progression-free survival showed a numerical trend favoring certepetide, both groups had a median PFS of 5.5 months. The trial includes two cohorts: Cohort A with 95 patients receiving a single dose, and Cohort B with 63 patients receiving two doses of certepetide. Data from Cohort B is expected in the coming months, with plans to advance to Phase 3 in early 2026.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its participation in the upcoming 2025 Sequire Investor Summit in San Juan, Puerto Rico.
The company's President and CEO, David J. Mazzo, PhD, will deliver a corporate overview presentation on Wednesday, January 22, 2025, at 10:00 a.m. Atlantic Standard Time. The summit is scheduled to take place from January 21-23, 2025.
Lisata Therapeutics (LSTA) announced completion of patient enrollment in all three cohorts of the Phase 1b/2a CENDIFOX trial, evaluating certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers. The investigator-initiated trial, led by Dr. Anup Kasi at The University of Kansas Cancer Center, enrolled 66 total patients across three cohorts: 35 with resectable/borderline resectable pancreatic cancer, 18 with high-grade colon and appendiceal cancer with peritoneal metastasis, and 13 with colon cancer with oligo-metastatic disease.
The open-label trial aims to assess safety and therapeutic effects of combining certepetide with neoadjuvant FOLFIRINOX regimens. Results are expected in 2025. The study will provide pre- and post-treatment tumor tissue data for immune profiling and long-term patient outcomes information.
